Skip to main content

Lessons learned from human HIV vaccine trials.

Publication ,  Journal Article
Pollara, J; Easterhoff, D; Fouda, GG
Published in: Curr Opin HIV AIDS
May 2017

PURPOSE OF REVIEW: The ability to induce broadly neutralizing antibody (bNAb) responses is likely essential for development of a globally effective HIV vaccine. Unfortunately, human vaccine trials conducted to date have failed to elicit broad plasma neutralization of primary virus isolates. Despite this limitation, in-depth analysis of the vaccine-induced memory B-cell repertoire can provide valuable insights into the presence and function of subdominant B-cell responses, and identify initiation of antibody lineages that may be on a path towards development of neutralization breadth. RECENT FINDINGS: Characterization of the functional capabilities of monoclonal antibodies isolated from a HIV-1 vaccine trial with modest efficacy has revealed mechanisms by which non-neutralizing antibodies are presumed to have mediated protection. In addition, B-cell repertoire analysis has demonstrated that vaccine boosts shifted the HIV-specific B-cell repertoire, expanding pools of cells with long third heavy chain complementarity determining regions - a characteristic of some bNAb lineages. SUMMARY: Detailed analysis of memory B-cell repertoires and evaluating the effector functions of isolated monoclonal antibodies expands what we can learn from human vaccine trails, and may provide knowledge that can enable rational design of novel approaches to drive maturation of subdominant disfavored bNAb lineages.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Opin HIV AIDS

DOI

EISSN

1746-6318

Publication Date

May 2017

Volume

12

Issue

3

Start / End Page

216 / 221

Location

United States

Related Subject Headings

  • Virology
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Antibodies
  • Clinical Trials as Topic
  • B-Lymphocytes
  • Antibodies, Neutralizing
  • Animals
  • AIDS Vaccines
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pollara, J., Easterhoff, D., & Fouda, G. G. (2017). Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS, 12(3), 216–221. https://doi.org/10.1097/COH.0000000000000362
Pollara, Justin, David Easterhoff, and Genevieve G. Fouda. “Lessons learned from human HIV vaccine trials.Curr Opin HIV AIDS 12, no. 3 (May 2017): 216–21. https://doi.org/10.1097/COH.0000000000000362.
Pollara J, Easterhoff D, Fouda GG. Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS. 2017 May;12(3):216–21.
Pollara, Justin, et al. “Lessons learned from human HIV vaccine trials.Curr Opin HIV AIDS, vol. 12, no. 3, May 2017, pp. 216–21. Pubmed, doi:10.1097/COH.0000000000000362.
Pollara J, Easterhoff D, Fouda GG. Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS. 2017 May;12(3):216–221.

Published In

Curr Opin HIV AIDS

DOI

EISSN

1746-6318

Publication Date

May 2017

Volume

12

Issue

3

Start / End Page

216 / 221

Location

United States

Related Subject Headings

  • Virology
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Antibodies
  • Clinical Trials as Topic
  • B-Lymphocytes
  • Antibodies, Neutralizing
  • Animals
  • AIDS Vaccines